Table 2.

Adherence, Serious Adverse Events, Secondary and follow-up outcomes by treatment assignment

	CBT (N=49)		TAU (N=50)		CBT4CBT w/monitoring (N=38)		Contrast 1: CBT v TAU			Contrast 2: CBT4CBT vs TAU
Variable	Mean	SD	Mean	SD	Mean	SD	f	P	p Eta2	f	P	p Eta2
General protocol adherence
Days in treatment (max=84)	42.8	30.7	55.5	27.3	61.7	26.8	4.85	.03	0.04	1.09	.30	0.01
Number of urine specimens collected	8	6.6	10.5	5.9	12	6.6	2.3	.13	0.02	1.1	.30	0.01
Total number of treatment sessionsa	4.1	3.4	5.6	3.1	6.9	3.57	4.99	.03	0.04	3.59	.06	0.03
Treatment-specific adherence
Total individual sessions	4.1	3.4	2.98	3.4	NA		2.53	.12	0.03
Total group sessions	NA		2.6	3.2	NA
Total monitoring sessions	NA		NA		6.8	3.6
Total CBT4CBT modules	NA		NA		5.5	2.3
Number of homework assignments completed	2.8	2.5	NA		2.2	2.4	0.23	.63	1.57	0.12	.73	0.65
Serious adverse eventsb	N	%	N	%	N	%	WaldX2	P	Exp (b)	Wald X2	p	Exp (b)
# (%) Participants with 1 or more SAEs during treatment-substance use or psychiatric	3	6.1	2	4.0	1	2.6	.23	.63	1.57	.12	.73	.65
Participants with 1 or more SAEs during treatment medical	2	4.1	1	2	3	7.9	.35	.55	2.09	1.49	.22	4.20
Participants with 1 or more SAEs during follow-up-substance use or psychiatric	1	2.7	1	2.3	3	8.6	.01	.91	1.17	1.35	.25	3.94
Participants with 1 or more SAEs during follow-up-medical	4	10.8	3	7	3	8.9	.36	.55	1.62	.07	.79	1.25
Secondary substance use outcomes	Mean	SD	Mean	SD	Mean	SD	f	P	p Eta2	f	p	p Eta2
Percent of urine specimens negative for all drugs	33.1	43.3	34.3	39.7	37	41.1	0.02	.89	.000	0.33	.57	.003
Percent cocaine-negative urine toxicology screens-all subjects	86.3	30.2	74.9	36.8	90.7	21.9	2.98	.09	.024	5.45	.02	.043
Percent cocaine-negative urine toxicology screens, cocaine users only (n's are 9, 17, 11)	63.6	46.2	39.4	37.3	75.3	34.4	2.29	.14	.060	5.73	.02	.140
Percent marijuana-negative urine toxicology screens-all subjects	44.5	47.1	43.6	44.2	48.8	43.3	0.01	.93	.000	0.27	.60	.002
Percent marijuana-negative urine toxicology screens, marijuana users only (n's are 23, 19, 18)	14.7	32.0	22.3	34.5	17.7	29.4	0.57	.45	.010	0.19	.66	.003
Categorical outcomes, indicators of clinical significance	Number	%	Number	%	Number	%	Wald	p	Exp (b)	Wald	p	Exp(b)
Provided no drug-positive urine specimens, last 2 weeks of treatment	9	18.4	9	18	13	34.2	0.00	.96	1.030	3.00	.09	2.370
Did not meet DSM-IV-R criteria for primary substance use diagnosis at 12 weeks (N's are 41, 47, 37)	16	51.6	15	42.9	20	66.7	0.51	.48	.710	3.61	.06	.380
Follow-up outcomes	Mean	SD	Mean	SD	Mean	SD	f	p	p Eta2	f	p	p Eta2
Percent days abstinent from drugs and alcohol (selfreport) Mean, SD	61.4	35.7	67.3	34.3	75.2	30.9	0.55	.46	.005	1.00	.32	.009
Urine specimen negative for all drugs (# negative/# collected)		%		%		%	WaldX2	p	Exp(b)	Wald X2	p	Exp (b)
One month follow-up (n=73)	6/18	33.3	16/29	55.2	12/26	46.2	2.10	.15	2.460	0.40	.51	1.440
Three month follow-up (n=79)	7/23	30.4	11/33	33.3	14/23	60.9	0.10	.82	1.140	4.00	.04	3.210
Six month follow-up (n=102)	8/33	24.2	12/39	30.9	15/30	50.0	0.40	.54	1.390	2.60	.11	.440

^aClinician CBT offered up to 12 individual sessions, TAU offered up to 12 group sessions with individual sessions as needed. CBT4CBT offered 12 clinical monitoring sessions plus up to 7 CBT4CBT modules

^bSAE indicates any Serious Adverse Event resulting in death or leading to hospitalization.